Referral C-121/17 (
Teva UK and Others
, 8 Mar 2017)
SPC for medicinal products
What are the criteria for deciding whether "the product is protected by a basic patent in force" in Article 3(a) of Regulation No. 469/2009?
Case details on the CJEU website